恩替卡韦联合门冬氨酸鸟氨酸治疗乙肝肝硬化肝性脑病效果观察

Observation of the effect of entecavir combined with ornithine aspartate in the treatment of patients with hepatitis B cirrhosis hepatic encephalopathy

目的:分析研究恩替卡韦联合门冬氨酸鸟氨酸针对乙肝肝硬化肝性脑病患者的治疗效果以及临床意义。方法:收治乙肝肝硬化肝性脑病患者80例,随机平分为两组,观察组通过恩替卡韦联合门冬氨酸鸟氨酸实施治疗,对照组通过门冬氨酸鸟氨酸治疗,对两组临床治疗效果行对比分析。结果:观察组的治疗优良率97.5%,高于对照组的87.5%,差异具有统计学意义(P<0.05)。结论:针对乙肝肝硬化肝性脑病患者,通过恩替卡韦联合门冬氨酸鸟氨酸的治疗效果显著。

Objective:To analyze the effects and clinical significance of entecavir combined with ornithine aspartate in the treatment of patients with hepatitis B cirrhosis hepatic encephalopathy.Methods:80 patients with hepatitis B cirrhosis hepatic encephalopathy were selected.They were randomly divided into the two groups.Patients in the observation group by entecavir combined with ornithine aspartate treatment.Patients in the control group treated by ornithine aspartate.The clinical effect of the two groups were compared and analyzed.Results:The excellent and good rate of patients in the observation group was 97.5%, higher than that 87.5% of the control group,and the difference was statistically significant(P<0.05).Conclusion:The effect of entecavir combined with ornithine aspartate in the treatment of patients with hepatitis B cirrhosis hepatic encephalopathy is obvious.